The plasma fractionation market is expected to grow at 6.5% CAGR from 2023 to 2029. It is expected to reach above USD 32.11 billion by 2029 from USD 18.22 billion in 2022.
In addition to salt, water, and enzymes, plasma delivers vital minerals, hormones, and proteins throughout the body. Because of this, plasma plays a crucial role in the treatment of several significant medical conditions. Its essential elements, such as antibodies, clotting factors, the proteins albumin and fibrinogen, can be dissected out and used as treatments for people with burns, shock, immune deficiency disorders, and other uncommon chronic illnesses. Blood plasma fractionation is the term used to describe the process of dividing the plasma into its individual proteins. These fractions have a wide range of therapeutic applications, such as the treatment of immune deficiencies or congenital diseases, the restoration of blood volume following trauma, and the development of highly efficient technologies for the inactivation of viral contaminants, such as hepatitis viruses and the human immunodeficiency virus (HIV).
For several immunologic, hematologic, and neurologic disorders, immunoglobulins are the first line of treatment. Due to technological improvements, the prevalence of numerous immunological illnesses has increased during the past ten years. Due to a rise in the number of individuals with immunodeficiency diagnoses, growing genetic research to characterize and identify immunodeficiency will also increase the clinical requirement for immunoglobulins. IVIg has a few on- and off-label indications, according to IG Living, a publication for the immune globulin (IG) community. In recent years, the use of immunoglobulin for off-label indications has surpassed that for on-label applications; off-label indications make up about 20–60% of its clinical use. These factors are driving market growth. Alpha-1-antitrypsin and immunoglobulins are expected to be used more frequently in a variety of medical specialties worldwide, which will likely fuel market expansion. The growth of blood collection facilities around the world is another significant factor propelling the development of this market.
| ATTRIBUTE | DETAILS |
| Study period | 2020-2029 |
| Base year | 2021 |
| Estimated year | 2022 |
| Forecasted year | 2022-2029 |
| Historical period | 2018-2020 |
| Unit | Value (USD BILLION), (THOUSAND UNITS) |
| Segmentation | By Product, By Application, By End-User and By Region. |
| By PRODUCT
|
|
| By APPLICATION
|
|
| By END-USER
|
|
| By Region
|
|
Plasma fractionation is one of the pharmaceutical industry's most strictly regulated segments. The potential for blood transfer, the attention of regulatory agencies relies on the safety and quality of fractionated plasma products due to borne pathogens (bacteria, viruses, and prions) and other disorders connected to transfusions (such as transmissible spongiform encephalopathies, including variant Creutzfeldt-Jakob disease). To ensure the caliber and security of plasma products, the WHO established standards for the plasma fractionation procedure. In addition to acting as a barrier for new players to enter the industry, the market's strict restrictions limit local small players' ability to develop internationally. While making investments in local or regional markets, like China, multinational corporations also encounter some difficulties. High costs associated with the plasma fractionation and restricted reimbursements and the disruptions that occur due to the incompetent alternatives are expected to be the major market restraints.
Influenza pandemics are sporadic, unforeseen occurrences that have a huge negative impact on society and the economy. In the US, there have been hospitalizations linked to influenza. The prevalence of these contagious diseases is predicted to rise and expected to create opportunities for items made from plasma.
The coronavirus pandemic positively impacted the market, it was projected that greater government spending and business involvement in plasma therapy research and development during pandemic accelerated market expansion. Additionally, the COVID-19 pandemic gave biotechnology and biopharma companies various opportunities to take part in R&D studies concerning plasma therapies.
Despite the current coronavirus pandemic's negative consequences on some enterprises, it has been noted that the global industry has expanded greatly over the previous several years. As the COVID-19 pandemic approached its worst stage, more people were negatively influenced by the viral infection and experienced major issues; this spurred the use of plasma as a treatment. However, because of increased government funding and business involvement in research and development, it is projected that the price of this therapy would increase, limiting market expansion. Additionally, the fact that fractionation therapy was successful in treating COVID-19 patients offered patients hope for plasma therapy.
The plasma fractionation market is worth USD 20.66 billion and is forecasted to reach above USD 32.11 billion by 2029.
Alpha-1-antitrypsin and immunoglobulins are expected to be used more frequently in a variety of medical specialties worldwide, which will likely fuel market expansion. The growth of blood collection facilities around the world is another significant factor propelling the development of this market.
The plasma fractionation market key players include Grifols S.A., CSL Limited, Takeda Pharmaceutical Company Limited, Octapharma AG, Kedrion S.p.A, LFB S.A., Biotest AG, Sanquin, Bio Products Laboratory Ltd., Intas Pharmaceuticals Ltd
A vital class of medicines known as protein products fractionated from human plasma is used to prevent, manage, and treat life-threatening illnesses brought on by injury, congenital deficits, immunologic disorders, or infections.
North America is anticipated to have the greatest market share for plasma fractionation worldwide in 2022 because more people are using plasma fractionated goods on a regular basis and more novel items are being developed. The North America plasma fractionation market accounts of 56% of the total global market share.
Plasma fractionation market is segmented based on by product, application, end user and region.
According to product type, the immunoglobulins segment is anticipated to hold the biggest market share for plasma fractionation in 2022. Due to the wide commercial availability of plasma-derived immunoglobulins in comparison to other plasma-derived products and the expanding use of immunoglobulins, particularly for the treatment of people with primary immune deficiencies or chronic inflammatory demyelinating polyneuropathy, this segment holds a significant market share.
According on application, the plasma fractionation market is anticipated to be dominated by the neurology segment in 2022. The substantial market share of this sector is related to elements like the widespread use of plasma-derived products for the treatment of neurological illnesses and the rising prevalence of neurological disorders.
According to end user, the plasma fractionation market is anticipated to be dominated by the hospitals & clinics segment in 2022. One of the main drivers of this segment's growth is the expanding usage of plasma-based products in numerous therapies, along with the expansion of hospitals and rising healthcare costs.
[caption id="attachment_14904" align="aligncenter" width="1920"]
The plasma fractionation market key players include Grifols S.A., CSL Limited, Takeda Pharmaceutical Company Limited, Octapharma AG, Kedrion S.p.A, LFB S.A., Biotest AG, Sanquin, Bio Products Laboratory Ltd., Intas Pharmaceuticals Ltd
January 11, 2023; Grifols a global leader in plasma medicines with more than 110 years contributing to improve the health and well-being of people, announced that its plasma-protein based fibrin sealant (FS) for controlling surgical bleeding obtained positive topline results from a phase 3b clinical trial in pediatric patients. Having met all primary and secondary endpoints, the study is expected to facilitate regulatory approval to expand the use of the FS-based biosurgery treatment, currently indicated for adults, to children and adolescents as well.
November 3, 2022; Grifols, a global leader in plasma-derived medicines and innovative diagnostic solutions, announced that its AlphaID™ At Home Genetic Health Risk Service, the first-ever free direct-to-consumer program in the U.S. to screen for genetic risk of alpha1-antitrypsin deficiency (alpha-1), has been cleared by the U.S. Food and Drug Administration (FDA). The service, also known as AlphaID™ At Home, is the company’s first FDA clearance for direct-to-consumer use. It will be available beginning in Q2 2023 for U.S. adults to screen for their genetic risk level of developing lung and/or liver disease related to alpha-1 without a medical prescription.
The plasma fractionation market by region includes North America, Asia-Pacific (APAC), Europe, South America, and Middle East & Africa (MEA).
Geographically, North America is anticipated to have the greatest market share for plasma fractionation worldwide in 2022 because more people are using plasma fractionated goods on a regular basis and more novel items are being developed. The North America plasma fractionation market accounts of 56% of the total global market share, however, during the forecast period, Asia-Pacific is expected to have the greatest CAGR. Collaborations between nations to establish plasma fractionation facilities, awareness campaigns to promote increased use of plasma and its fractionation, the rise in various medical conditions, such as the rising prevalence of hemophilia in nations like China and India that necessitate the use of plasma fractionation products, and the rising geriatric population in the Asia-Pacific region are what are driving the market growth in that region.
The United States is leading the worldwide plasma fractionation market in North America with the highest CAGR because the population there is more aware of the wide-ranging advantages of plasma. China is the market leader for plasma fractionation in Asia-Pacific because of rising demand for the procedure and rising public health awareness. Due to its high elderly population and immune deficiency diseases, Germany is currently dominating the market in Europe with the highest share.
[caption id="attachment_14905" align="aligncenter" width="1920"]
Want to know more about the report or any specific requirement?
We asked them to research ‘ Equipment market’ all over the world, and their whole arrangement was helpful to us. thehealthanalytics.com insightful analysis and reports contributed to our current analysis and in creating a future strategy. Besides, the te
We asked them to research ‘Equipment market’ all over the world, and their whole arrangement was helpful to us. thehealthanalytics.com insightful analysis and reports contributed to our current analysis and in creating a future strategy. Besides, the te
Our Report’s database covers almost all topics of all regions over the Globe.
Tie ups with top publishers around the globe.
Complete pre and post sales support.
Complete secure payment process.